Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum beta 2-microglobulin Levels
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, HD[Kim, Hyung-Don] | - |
dc.contributor.author | Cho, H[Cho, Hyungwoo] | - |
dc.contributor.author | Kim, S[Kim, Shin] | - |
dc.contributor.author | Lee, K[Lee, Kyoungmin] | - |
dc.contributor.author | Kang, EH[Kang, Eun Hee] | - |
dc.contributor.author | Park, JS[Park, Jung Sun] | - |
dc.contributor.author | Park, CS[Park, Chan-Sik] | - |
dc.contributor.author | Huh, J[Huh, Jooryung] | - |
dc.contributor.author | Ryu, JS[Ryu, Jin Sook] | - |
dc.contributor.author | Lee, SW[Lee, Sang-Wook] | - |
dc.contributor.author | Yoon, DH[Yoon, Dok-Hyun] | - |
dc.contributor.author | Kim, SJ[Kim, Seok Jin] | - |
dc.contributor.author | Ko, YH[Ko, Young Hyeh] | - |
dc.contributor.author | Kim, WS[Kim, Won Seog] | - |
dc.contributor.author | Suh, C[Suh, Cheolwon] | - |
dc.date.accessioned | 2021-08-25T01:43:41Z | - |
dc.date.available | 2021-08-25T01:43:41Z | - |
dc.date.created | 2021-08-25 | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/89439 | - |
dc.description.abstract | Purpose We aimed to investigate the prognostic value of serum beta 2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system. Materials and Methods A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and/or serum beta 2-microglobulin levels. A risk-stratifying classification system incorporating serum beta 2-microglobulin levels was proposed and validated in an independent validation cohort (n=60). Results The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum beta 2-microglobulin levels (> 2 mg/L) had significantly worse progression-free survival (PFS) and overall survival (OS) (p < 0.01 for both). Serum beta 2-microglobulin levels further stratified patients in the low-risk and high-risk groups in terms of PFS (p=0.010 and p=0.044, respectively) and OS (p=0.014 and p=0.026, respectively). Multivariate analyses revealed that a high serum beta 2-microglobulin level (> 2 mg/L) was independently associated with a shorter PFS (hazards ratio [HR], 3.56; p=0.047) and OS (HR, 4.66; p=0.043). The new classification system incorporating the serum beta 2-microglobulin level allowed the stratification of patients into three distinct risk subgroups with 5-year OS rates of 100%, 89.5%, and 62.5%. In an independent cohort of BL, the system was validated by stratifying patients with different survival outcomes. Conclusion Serum beta 2-microglobulin level is an independent prognostic factor for BL patients. The proposed beta 2-microglobulin-based classification system could stratify patients with distinct survival outcomes, which may help define appropriate treatment approaches for individual patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.subject | ADULT BURKITTS | - |
dc.subject | CELL LYMPHOMA | - |
dc.subject | CANCER | - |
dc.subject | HODGKIN | - |
dc.subject | BETA(2)-MICROGLOBULIN | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | SURVIVAL | - |
dc.subject | LEUKEMIA | - |
dc.subject | THERAPY | - |
dc.subject | IMPACT | - |
dc.title | Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum beta 2-microglobulin Levels | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, SJ[Kim, Seok Jin] | - |
dc.contributor.affiliatedAuthor | Ko, YH[Ko, Young Hyeh] | - |
dc.contributor.affiliatedAuthor | Kim, WS[Kim, Won Seog] | - |
dc.identifier.doi | 10.4143/crt.2020.1060 | - |
dc.identifier.scopusid | 2-s2.0-85111481374 | - |
dc.identifier.wosid | 000674117200027 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.53, no.3, pp.847 - 856 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 53 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 847 | - |
dc.citation.endPage | 856 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | ADULT BURKITTS | - |
dc.subject.keywordPlus | CELL LYMPHOMA | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | HODGKIN | - |
dc.subject.keywordPlus | BETA(2)-MICROGLOBULIN | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | LEUKEMIA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | Burkitt lymphoma | - |
dc.subject.keywordAuthor | beta 2-microglobulin | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Risk stratification | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.